Attached files
| file | filename |
|---|---|
| 8-K - 8-K - CALMARE THERAPEUTICS Inc | s107503_8k.htm |
Exhibit 16.1
September 14, 2017
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549-7561
Dear Sirs/Mesdames:
We have read Item 4.01 of Calmare Therapeutics Incorporated Form 8-K dated September 14, 2017, and have the following comments:
| 1. | We agree with the statements made in the first, second, third and fourth paragraphs of Item 4.01(a). |
| 2. | We have no basis on which to agree or disagree with the statements made in the fifth and sixth paragraphs of Item 4.01(a). |
Yours truly,
/s/ Mayer Hoffman McCann CPAs
The New York Practice of Mayer Hoffman McCann P.C.
New York, New York